OAB-012: Early and sustained negative minimal residual disease (MRDneg) after idecabtagene vicleucel (ide-cel) defines a subset of multiple myeloma (MM) patients in KarMMa achieving prolonged survival
Titel:
OAB-012: Early and sustained negative minimal residual disease (MRDneg) after idecabtagene vicleucel (ide-cel) defines a subset of multiple myeloma (MM) patients in KarMMa achieving prolonged survival
Auteur:
Paiva, Bruno Manrique, Irene Rytlewski, Julie Campbell, Timothy Kazanecki, Christian Martin, Nathan Kaiser, Shari Anderson, Larry Berdeja, Jesus G. Lonial, Sagar Raje, Noopur Lin, Yi Moreau, Philippe San-Miguel, Jesus Munshi, Nikhil